Topics

Low-grade gliomas | Treatment | Clinical trials | Selumetinib

Home > Publications > Topics > Low-grade gliomas > Treatment > Clinical trials > Selumetinib

Fangusaro J, Onar-Thomas A, Young Poussaint T, Lensing S, Ligon AH, Lindeman N, Banerjee A, Kilburn LB, Lenzen A, Pillay-Smiley N, Pollack IF, Robison NJ, Partap S, Qaddoumi I, Landi D, Jones DTW, Stewart CF, Fouladi M, Dunkel IJ.
A Phase 2 PBTC Study of Selumetinib for Recurrent/Progressive Pediatric Low-Grade Glioma: Strata 2, 5, and 6 with Long-term Outcomes on Strata 1, 3, and 4.
Neuro Oncol. 2025 Apr 17:noaf065. doi: 10.1093/neuonc/noaf065. PMID: 40241281. Interventional study˰ ˍ

Arakawa Y, Saito R, Kanemura Y, Mishima K, Koriyama S, Narita Y, Kumabe T, Motomura K, Sugiyama K, Yamasaki F, Mukasa A, Kanamori M, Kuga D, Nagane M, Kakurai Y, Isobe K, Nakamura H.
Phase II study of safusidenib erbumine in patients with chemotherapy- and radiotherapy-naïve isocitrate dehydrogenase 1-mutated WHO grade 2 gliomas.
Neuro Oncol. 2025 Nov 8:noaf258. doi: 10.1093/neuonc/noaf258. PMID: 41206766. Interventional study. ˍ